Fig. 5: Median OS at 10−5. | Leukemia

Fig. 5: Median OS at 10−5.

From: Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Fig. 5: Median OS at 10−5.The alternative text for this image may have been generated using AI.

A In the efficacy population. B by MRD statusa. aMRD was determined by NGF and NGS methods, and MRD- rate was determined by combining both methods in the case of at least 1 method yielding negative results and the other method showing no positive result at the same time. d dexamethasone, Isa isatuximab, MRD- minimal residual disease negativity, NC not calculable, OS overall survival, R lenalidomide, V bortezomib.

Back to article page